F. Binder-foucard, N. Bossard, P. Delafosse, A. Belot, A. Woronoff et al., Cancer incidence and mortality in France over the 1980???2012 period: Solid tumors, Revue d'??pid??miologie et de Sant?? Publique, vol.62, issue.2, pp.95-108, 2014.
DOI : 10.1016/j.respe.2013.11.073

J. Mclaughlin, L. Lipworth, and R. Tarone, Epidemiologic Aspects of Renal Cell Carcinoma, Seminars in Oncology, vol.33, issue.5, pp.527-560, 2006.
DOI : 10.1053/j.seminoncol.2006.06.010

F. Algaba, H. Akaza, A. López-beltrán, G. Martignoni, H. Moch et al., Current Pathology Keys of Renal Cell Carcinoma, European Urology, vol.60, issue.4, pp.634-677, 2011.
DOI : 10.1016/j.eururo.2011.06.047

A. Bradley, Y. Lim, and F. Singh, Imaging features, follow-up, and management of incidentally detected renal lesions, Clinical Radiology, vol.66, issue.12, pp.1129-1168, 2011.
DOI : 10.1016/j.crad.2011.07.044

S. Nielsen, L. Rhodes, I. Blanco, W. Chung, C. Eng et al., Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome, Journal of Clinical Oncology, vol.34, issue.18, pp.2172-81, 2016.
DOI : 10.1200/JCO.2015.65.6140

W. Kaelin, The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer, Clinical Cancer Research, vol.10, issue.18, pp.6290-6295, 2004.
DOI : 10.1158/1078-0432.CCR-sup-040025

S. Gunningham, M. Currie, C. Han, K. Turner, P. Scott et al., Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia, Cancer Res. 1 avr, vol.61, issue.7, pp.3206-3217, 2001.

J. Folkman and M. Klagsbrun, Angiogenic factors, Science, vol.235, issue.4787, pp.442-449, 1987.
DOI : 10.1126/science.2432664

B. Escudier, A. Pluzanska, P. Koralewski, A. Ravaud, S. Bracarda et al., Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, The Lancet, vol.370, issue.9605, pp.2103-2114, 2007.
DOI : 10.1016/S0140-6736(07)61904-7

B. Rini, S. Halabi, J. Rosenberg, W. Stadler, D. Vaena et al., Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206, Journal of Clinical Oncology, vol.28, issue.13, pp.2137-2180, 2010.
DOI : 10.1200/JCO.2009.26.5561

R. Motzer, T. Hutson, P. Tomczak, M. Michaelson, R. Bukowski et al., Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.115-139, 2007.
DOI : 10.1056/NEJMoa065044

R. Motzer, T. Hutson, D. Cella, J. Reeves, R. Hawkins et al., Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.369, issue.8, pp.722-753, 2013.
DOI : 10.1056/NEJMoa1303989

B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard et al., Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-159, 2007.
DOI : 10.1056/NEJMoa060655

R. Motzer, B. Escudier, P. Tomczak, T. Hutson, M. Michaelson et al., Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial, The Lancet Oncology, vol.14, issue.6, pp.552-62, 2013.
DOI : 10.1016/S1470-2045(13)70093-7

T. Choueiri, B. Escudier, T. Powles, P. Mainwaring, B. Rini et al., Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1814-1837, 2015.
DOI : 10.1056/NEJMoa1510016

S. Négrier, G. Gravis, D. Pérol, C. Chevreau, R. Delva et al., Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial, The Lancet Oncology, vol.12, issue.7, pp.673-80, 2011.
DOI : 10.1016/S1470-2045(11)70124-3

R. Motzer, B. Escudier, S. Oudard, T. Hutson, C. Porta et al., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, The Lancet, vol.372, issue.9637, pp.449-56, 2008.
DOI : 10.1016/S0140-6736(08)61039-9

W. Wiecek and H. Karcher, Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma, PLOS ONE, vol.373, issue.34, p.155389, 2016.
DOI : 10.1371/journal.pone.0155389.s004

R. Motzer, B. Escudier, D. Mcdermott, S. George, H. Hammers et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1803-1816, 2015.
DOI : 10.1056/NEJMoa1510665

S. Négrier, B. Escudier, F. Gomez, J. Douillard, A. Ravaud et al., Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie, Annals of Oncology, vol.13, issue.9, pp.1460-1468, 2002.
DOI : 10.1093/annonc/mdf257

B. Crepel, B. Escudier, J. Machiels, M. Staehler, A. Ravaud et al., Comparison of two major prognostic models for patients with metastatic renal cell carcinoma treated in the contemporary era of targeted therapies., Journal of Clinical Oncology, vol.29, issue.15_suppl, p.2011
DOI : 10.1200/jco.2011.29.15_suppl.4660

D. Heng, W. Xie, M. Regan, M. Warren, A. Golshayan et al., Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor???Targeted Agents: Results From a Large, Multicenter Study, Journal of Clinical Oncology, vol.27, issue.34, pp.5794-5803, 2009.
DOI : 10.1200/JCO.2008.21.4809

B. Delahunt, Advances and controversies in grading and staging of renal cell carcinoma, Modern Pathology, vol.19, issue.2, pp.24-36, 2009.
DOI : 10.1309/0FT8WTDKREFHHP4P

J. Allende and C. Allende, Protein kinases. 4 Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation, FASEB J Off Publ Fed Am Soc Exp Biol. mars, vol.9, issue.5, pp.313-336, 1995.

D. Canton and D. Litchfield, The shape of things to come: An emerging role for protein kinase CK2 in the regulation of cell morphology and the cytoskeleton, Cellular Signalling, vol.18, issue.3, pp.267-75, 2006.
DOI : 10.1016/j.cellsig.2005.07.008

L. Chantalat, D. Leroy, O. Filhol, A. Nueda, M. Benitez et al., Crystal structure of the human protein kinase CK2 regulatory subunit reveals its zinc finger-mediated dimerization, The EMBO Journal, vol.18, issue.11, pp.2930-2970, 1999.
DOI : 10.1093/emboj/18.11.2930

V. Martel, O. Filhol, A. Nueda, and C. Cochet, Dynamic Localization/Association of Protein Kinase CK2 Subunits in Living Cells, Annals of the New York Academy of Sciences, vol.10, issue.1, pp.272-279, 2002.
DOI : 10.1111/j.1749-6632.2002.tb04648.x

V. Martel, O. Filhol, A. Nueda, D. Gerber, M. Benitez et al., Visualization and molecular analysis of nuclear import of protein kinase CK2 subunits in living cells, Mol Cell Biochem. nov, vol.227, issue.1?2, pp.81-90, 2001.
DOI : 10.1007/978-1-4615-1723-8_10

T. Buchou and C. Cochet, La prot??ine kinase CK2, une enzyme qui cultive la diff??rence, m??decine/sciences, vol.19, issue.6-7, pp.709-725, 2003.
DOI : 10.1051/medsci/20031967709

D. Lou, I. Dominguez, P. Toselli, E. Landesman-bollag, O. Brien et al., The Alpha Catalytic Subunit of Protein Kinase CK2 Is Required for Mouse Embryonic Development, Molecular and Cellular Biology, vol.28, issue.1, pp.131-140, 2008.
DOI : 10.1128/MCB.01119-07

M. Hung, Y. Lin, J. Mao, I. Kim, Z. Xu et al., Functional Polymorphism of the CK2?? Intronless Gene Plays Oncogenic Roles in Lung Cancer, PLoS ONE, vol.16, issue.7, p.11418, 2010.
DOI : 10.1371/journal.pone.0011418.s001

M. Laramas, D. Pasquier, O. Filhol, F. Ringeisen, J. Descotes et al., Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer, Eur J Cancer Oxf Engl mars, vol.43, issue.5, pp.928-962, 1990.
URL : https://hal.archives-ouvertes.fr/inserm-00413230

J. Kim, J. Eom, J. Cheong, A. Choi, J. Lee et al., Protein Kinase CK2?? as an Unfavorable Prognostic Marker and Novel Therapeutic Target in Acute Myeloid Leukemia, Clinical Cancer Research, vol.13, issue.3, pp.1019-1047, 2007.
DOI : 10.1158/1078-0432.CCR-06-1602

S. Giusiano, C. Cochet, O. Filhol, E. Duchemin-pelletier, V. Secq et al., Protein kinase CK2?? subunit over-expression correlates with metastatic risk in breast carcinomas: Quantitative immunohistochemistry in tissue microarrays, European Journal of Cancer, vol.47, issue.5, pp.792-801, 1990.
DOI : 10.1016/j.ejca.2010.11.028

K. Ahmad, G. Wang, and K. Ahmed, Intracellular Hydrogen Peroxide Production Is an Upstream Event in Apoptosis Induced by Down-Regulation of Casein Kinase 2 in Prostate Cancer Cells, Molecular Cancer Research, vol.4, issue.5, pp.331-339, 2006.
DOI : 10.1158/1541-7786.MCR-06-0073

A. Deshiere, E. Duchemin-pelletier, E. Spreux, D. Ciais, F. Combes et al., Unbalanced expression of CK2 kinase subunits is sufficient to drive epithelial-to-mesenchymal transition by Snail1 induction, Oncogene, vol.61, issue.11, pp.1373-83, 2013.
DOI : 10.1002/ijc.24177

O. Filhol, S. Giacosa, Y. Wallez, and C. Cochet, Protein kinase CK2 in breast cancer: the CK2?? regulatory subunit takes center stage in epithelial plasticity, Cellular and Molecular Life Sciences, vol.8, issue.10, pp.3305-3327, 2015.
DOI : 10.1007/s00018-015-1929-8

G. Stalter, S. Siemer, E. Becht, M. Ziegler, K. Remberger et al., Asymmetric Expression of Protein Kinase CK2 Subunits in Human Kidney Tumors, Biochemical and Biophysical Research Communications, vol.202, issue.1, pp.141-148, 1994.
DOI : 10.1006/bbrc.1994.1904

V. Moucadel, R. Prudent, C. Sautel, F. Teillet, C. Barette et al., Antitumoral activity of allosteric inhibitors of Protein kinase CK2, Oncotarget, vol.2, issue.12, pp.997-1010, 2011.
DOI : 10.18632/oncotarget.361

M. Tadj, V. Arnoux, M. Mousseau, J. Descotes, J. Quesada et al., A moncentric review of targeted therapy on overall survival in metastatic renal clear cell carcinoma, J Clin Oncol, vol.31, issue.15593, p.2013

M. Tadj, Amélioration de la survie globale des patients porteurs de cancer du rein métastatique gr?ace aux thérapies ciblées : revue monocentrique depuis, p.824923, 2000.

B. Delahunt, D. Sika-paotonu, P. Bethwaite, W. Jordan, T. Magi-galluzzi et al., Grading of Clear Cell Renal Cell Carcinoma Should be Based on Nucleolar Prominence, The American Journal of Surgical Pathology, vol.35, issue.8, pp.1134-1143, 2011.
DOI : 10.1097/PAS.0b013e318220697f

D. Minardi, G. Lucarini, R. Mazzucchelli, G. Milanese, D. Natali et al., PROGNOSTIC ROLE OF FUHRMAN GRADE AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN pT1a CLEAR CELL CARCINOMA IN PARTIAL NEPHRECTOMY SPECIMENS, The Journal of Urology, vol.174, issue.4, pp.1208-1220, 2005.
DOI : 10.1097/01.ju.0000173078.57871.2d

D. Minardi, G. Lucarini, A. Filosa, G. Milanese, A. Zizzi et al., Prognostic Role of Tumor Necrosis, Microvessel Density, Vascular Endothelial Growth Factor and Hypoxia Inducible Factor-1?? in Patients with Clear Cell Renal Carcinoma after Radical Nephrectomy in a Long Term Follow-up, International Journal of Immunopathology and Pharmacology, vol.66, issue.2, pp.447-55, 2008.
DOI : 10.1097/00000478-198210000-00007

S. Pastorekova, Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma, Oncology Letters
DOI : 10.3892/ol.2012.1001

S. Kruck, C. Eyrich, M. Scharpf, K. Sievert, F. Fend et al., Impact of an Altered Wnt1/??-Catenin Expression on Clinicopathology and Prognosis in Clear Cell Renal Cell Carcinoma, International Journal of Molecular Sciences, vol.14, issue.6, pp.10944-57, 2013.
DOI : 10.3390/ijms140610944

S. Dutertre, S. Descamps, and C. Prigent, On the role of aurora-A in centrosome function, Oncogene, vol.21, issue.40, pp.6175-83, 2002.
DOI : 10.1038/sj.onc.1205775

URL : https://hal.archives-ouvertes.fr/inserm-00966247

T. Kurahashi, H. Miyake, I. Hara, and M. Fujisawa, Significance of Aurora-A expression in renal cell carcinoma, Urologic Oncology: Seminars and Original Investigations, vol.25, issue.2, pp.128-161, 2007.
DOI : 10.1016/j.urolonc.2006.06.001

M. Schlüter and B. Margolis, Apicobasal polarity in the kidney, Experimental Cell Research, vol.318, issue.9, pp.1033-1042, 2012.
DOI : 10.1016/j.yexcr.2012.02.028

F. Dugay, L. Goff, X. Rioux-leclerq, N. Chesnel, F. Jouan et al., Overexpression of the polarity protein PAR-3 in clear cell renal cell carcinoma is associated with poor prognosis, International Journal of Cancer, vol.135, issue.9, pp.2051-60, 2014.
DOI : 10.1002/ijc.28548

URL : https://hal.archives-ouvertes.fr/hal-01010658

J. Dagher, F. Dugay, N. Rioux-leclercq, G. Verhoest, E. Oger et al., Cytoplasmic PAR-3 protein expression is associated with adverse prognostic factors in clear cell renal cell carcinoma and independently impacts survival, Human Pathology, vol.45, issue.8, pp.1639-1685, 2014.
DOI : 10.1016/j.humpath.2014.03.018

URL : https://hal.archives-ouvertes.fr/hal-01058621

X. Mao, P. Li, Y. Ren, J. Li, C. Zhou et al., Cell polarity protein CRB3 is an independent favorable prognostic factor for clear cell renal cell carcinoma, International Journal of Oncology, vol.46, issue.2, pp.657-66, 2015.
DOI : 10.3892/ijo.2014.2763

R. Kalluri and R. Weinberg, The basics of epithelial-mesenchymal transition, Journal of Clinical Investigation, vol.119, issue.6, pp.1420-1428, 2009.
DOI : 10.1172/JCI39104

K. Harada, H. Miyake, Y. Kusuda, and M. Fujisawa, Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy, BJU International, vol.5, issue.11c, pp.1131-1137, 2012.
DOI : 10.1111/j.1464-410X.2012.11297.x

I. Frew and H. Moch, A Clearer View of the Molecular Complexity of Clear Cell Renal Cell Carcinoma, Annual Review of Pathology: Mechanisms of Disease, vol.10, issue.1, pp.263-89, 2015.
DOI : 10.1146/annurev-pathol-012414-040306

J. Brugarolas, Molecular Genetics of Clear-Cell Renal Cell Carcinoma, Journal of Clinical Oncology, vol.32, issue.18, pp.1968-76, 2014.
DOI : 10.1200/JCO.2012.45.2003

R. Joseph, P. Kapur, D. Serie, M. Parasramka, T. Ho et al., Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression, The Journal of Urology, vol.195, issue.1, pp.180-187, 2016.
DOI : 10.1016/j.juro.2015.07.113

P. Kapur, S. Peña-llopis, A. Christie, L. Zhrebker, A. Pavía-jiménez et al., Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation, The Lancet Oncology, vol.14, issue.2, pp.159-67, 2013.
DOI : 10.1016/S1470-2045(12)70584-3

M. Montenarh, Protein Kinase CK2 and Angiogenesis, Advances in Clinical and Experimental Medicine, vol.23, issue.2, pp.153-161, 2014.
DOI : 10.17219/acem/37040

D. Seldin, E. Landesman-bollag, M. Farago, N. Currier, D. Lou et al., CK2 as a positive regulator of Wnt signalling and tumourigenesis, Molecular and Cellular Biochemistry, vol.20, issue.1-2, pp.63-70, 2005.
DOI : 10.1007/s11010-005-3078-0

Y. Peng, C. Wong, Y. Nakajima, R. Tyers, A. Sarkeshik et al., Overlapping kinetochore targets of CK2 and Aurora B kinases in mitotic regulation, Molecular Biology of the Cell, vol.22, issue.15, pp.2680-2689, 2011.
DOI : 10.1091/mbc.E10-11-0915

A. Ulges, M. Klein, S. Reuter, B. Gerlitzki, M. Hoffmann et al., Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo, Nature Immunology, vol.112, issue.3, pp.267-75, 2015.
DOI : 10.4049/jimmunol.1004136

A. Siddiqui-jain, D. Drygin, N. Streiner, P. Chua, F. Pierre et al., CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy, Cancer Research, vol.70, issue.24, pp.10288-98, 2010.
DOI : 10.1158/0008-5472.CAN-10-1893